1. Articles from Fool.com

    fool.com

  2. 25-48 of 68 « 1 2 3 »
    1. CenturyLink Has a "Friendly" Activist: What It Means for Shareholders

      CenturyLink Has a "Friendly" Activist: What It Means for Shareholders

      Suffering shareholders of the telecoms company CenturyLink ( NYSE:CTL ) got a boost on May 8 when activist investor Keith Meister revealed a 5.5% stake in the company, calling the shares undervalued by at least 40% and offering some "friendly" advice on management succession as the company merges with Level 3 Communications ( NYSE:LVLT ) . As both I and fellow Fool Steve Symington have written before, CenturyLink's merger with Level 3 is a smart idea...

      Read Full Article
    2. Unilever Gives Internal Activism a Shot

      Unilever Gives Internal Activism a Shot

      Unilever plc (NYSE: UL) released its plan for proceeding with life after spurning The Kraft Heinz Company 's (NASDAQ: KHC) $143 billion takeover bid in mid-February. While there aren't many other companies with the heft of Kraft Heinz that could give Unilever a similar scare, an activist shareholder group acquiring just a few percentage points of ownership could still make life unpleasant for the company...

      Read Full Article
    3. Here's How Carl Icahn's Portfolio Is Changing

      Here's How Carl Icahn's Portfolio Is Changing

      Activist investor Carl Icahn is famous for making big bets on companies, and then arm-wrestling their executives into embracing shareholder friendly behaviors. Currently, Icahn owns stakes in 19 businesses that are valued at nearly $20 billion, and while there's no guarantee he'll successfully convince all those companies to pay dividends, divest non-core assets, or sell themselves lock stock and barrel, I wouldn't bet against him...

      Read Full Article
    4. Who Could Buy Bristol-Myers Squibb?

      Who Could Buy Bristol-Myers Squibb?

      Billionaire activist investor Carl Icahn has reportedly set his sights on Bristol-Myers Squibb ( NYSE:BMY ) , a $90 billion-market-cap biopharma that's carving out an important leadership position in immuno-oncology. If past is prologue, Icahn's about to start advocating for big changes at Bristol-Myers Squibb, and those could include an outright sale. Finding a buyer, however, might not be easy...

      Read Full Article
      Mentions: Leadership
    5. Here’s Something That Bank of America Shareholders Can Get Excited About

      Here’s Something That Bank of America Shareholders Can Get Excited About

      Shareholders of Bank of America ( NYSE:BAC ) could be in for a windfall if the incoming presidential administration follows through on its promise to roll-back the 2010 Dodd-Frank Act. There are a number of ways this would help Bank of America, but one of the most important involves eliminating the Federal Reserve's veto power over bank capital plans -- i.e., dividend and stock repurchase plans...

      Read Full Article
    6. Johnson & Johnson Throws Caution to the Wind With a Large Bid for Actelion

      Johnson & Johnson Throws Caution to the Wind With a Large Bid for Actelion

      Healthcare conglomerate Johnson & Johnson ( NYSE:JNJ ) is a trend setter in the sector. Anytime it makes a move, its drug and device peers and Wall Street monitor closely. Though Johnson & Johnson has a cadre of organically developed pharmaceutical products, medical devices, and consumer healthcare products, it's also used M&A throughout its history to expand its product line, further its global reach, and boost its growth prospects...

      Read Full Article
      Mentions: MDC Partners
    7. Why DepoMed's Shares Are Jumping 12% Today

      Why DepoMed's Shares Are Jumping 12% Today

      Following reports that its board of directors may be willing to entertain offers, DepoMed, Inc. (NASDAQ: DEPO) shares are rallying 12% at noon EST. So what Motley Fool Founders Issue New Stock Buy Alert Starboard Value LP investor Jeffrey Smith has been lobbying for DepoMed to put itself up for sale since acquiring a nearly 10% stake earlier this year, and it seems that only a year after rejecting a $33-per-share acquisition offer from Horizon Pharma (NASDAQ: HZNP) , the board is listening. Interest in......

      Read Full Article
    8. Does This Settlement Put a Hershey Company Buyout Back on the Table?

      Does This Settlement Put a Hershey Company Buyout Back on the Table?

      After years of being plagued by scandals, the trust that oversees chocolate maker Hershey is being forced to change its composition, which could open it up to accepting a takeover offer. Image Source: The Motley Fool Once again, Hershey ( NYSE:HSY ) has rejected an attempted buyout, but a settlement reached between its board of trustees and Pennsylvania's attorney general could mean another takeover offer may soon be in the works...

      Read Full Article
    25-48 of 68 « 1 2 3 »
  1. Categories

    1. BoardProspects Features:

      BoardBlogs, BoardKnowledge, BoardMoves, BoardNews, BoardProspects Announcements, BoardProspects CEO, CEO Blog, In the News, Partner Publications, Question of The Week, Sponsored Content